TickerFacts.

Lexicon Pharmaceuticals, Inc. (LXRX): Cost of Revenue

Annual figures by period end, from SEC filings.

$274.0K
Year ended 2025-12-31
$358.0K
Trailing 12 months to 2026-06-30
-32.3%
5-year compound annual growth
$3.23M2015-12-31: $02016-12-31: $02017-12-31: $1.90M2018-12-31: $2.49M2019-12-31: $3.23M2020-12-31: $1.93M2021-12-31: $02022-12-31: $02023-12-31: $85.0K2024-12-31: $616.0K2025-12-31: $274.0K$274.0K
2015-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$274.0K-55.5%2026-03-05, From 2025-01-01
2024-12-31$616.0K+624.7%2026-03-05, From 2024-01-01
2023-12-31$85.0Kn/a2026-03-05, From 2023-01-01
2022-12-31$0n/a2025-03-07, From 2022-01-01
2021-12-31$0-100.0%2024-03-25, From 2021-01-01
2020-12-31$1.93M-40.3%2023-03-03, From 2020-01-01
2019-12-31$3.23M+29.7%2022-03-10, From 2019-01-01
2018-12-31$2.49M+31.2%2021-03-12, From 2018-01-01
2017-12-31$1.90Mn/a2020-03-12, From 2017-01-01
2016-12-31$0n/a2019-03-15, From 2016-01-01
2015-12-31$0n/a2018-03-01, From 2015-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Lexicon Pharmaceuticals, Inc. (LXRX)2025-12-31$274.0K-55.5%
Ocular Therapeutix, Inc (OCUL)2025-12-31$6.57M+16.9%
Agios Pharmaceuticals, Inc. (AGIO)2025-12-31$6.34M+52.3%
Nektar Therapeutics (NKTR)2025-12-31$0-100.0%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$18.55M+3.8%
Cumberland Pharmaceuticals Inc (CPIX)2025-12-31$6.67M+1.2%
Integrated Biopharma Inc (INBP)2026-06-30$43.07M-11.7%
Aytu Biopharma, Inc (AYTU)2026-06-30$20.75M+1.0%
Journey Medical Corp (DERM)2025-12-31$20.92M+0.2%

Compare LXRX, OCUL, AGIO, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗